CN1406622A - High efficiency weight reduction medicine or health-care food - Google Patents
High efficiency weight reduction medicine or health-care food Download PDFInfo
- Publication number
- CN1406622A CN1406622A CN01142084A CN01142084A CN1406622A CN 1406622 A CN1406622 A CN 1406622A CN 01142084 A CN01142084 A CN 01142084A CN 01142084 A CN01142084 A CN 01142084A CN 1406622 A CN1406622 A CN 1406622A
- Authority
- CN
- China
- Prior art keywords
- fat
- reducing
- medicine
- health food
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An efficient weight-lossing medicine or health-care food is prepared from carnitine (40-45 wt.%), chitosan (30-35), konjak (20-25) and flavouring (5-10).
Description
Technical field
The invention belongs to the medicines and health protection field, relate to a kind of medicine or health food, relate in particular to a kind of medicine or health food that utilizes Rhizoma amorphophalli, carnitine, chitosan to make for primary raw material with weight losing function.
Background technology
Obesity is a kind of modern civilization disease, because the raising of people's living standard and unreasonable and some other factor of nutrition, obese people presents the trend that rises year by year in worldwide.At present, 1,200,000,000 obesity patients are arranged approximately in the world, the incidence of obesity of American-European developed country is up to more than 40%, and China's incidence of obesity is also increasing rapidly, and some areas reach more than 30%.Obesity not only influences attractive in appearancely, is more classified as one of three human big diseases because of its dangers to health by current medical circle.How to cure obesity, become a global difficult problem together.
Over nearly 50 years, about obesity people Fat Distribution type and and the research of lipid metabolism complication mutual relation make substantial progress.To the heredity and the energy metabolism of adiposis patient, the research of the form and function of adipose cell and metabolism adjusting, differentiation mechanism etc. makes people to the pathogenesis of obesity darker understanding arranged.
Fat cause is very complicated, comprises that inherited genetic factors, neuroendocrine factor, dietary factors, social environmental factor and energy metabolism are unusual etc., and present most experts think that obesity is the coefficient result of nature-nurture factor.To a certain extent, the complexity of fat cause has determined the arduousness and the complexity of fat-reducing.
Product on China's weight-reducing product market is big to being divided into five big classes now: 1, healthcare food, 2, teas, 3, drug class, 4, topical class, 5, instrument class.Wherein Kang Er longevity, Mei Fule, Ning Hong, storm, V
26, exquisite, Ya Lai, more tender beautiful 70% the market share that occupied.
Three approach is mainly passed through in the exploitation of domestic diet food: 1, based on the conditioning diet, the exploitation diet food is as refined Lay; 2, develop diet food with the medicine-food two-purpose Chinese herbal medicine resource, as Kang Ershou, Mei Fule etc.; 3, become to assign to make diet food by special efficacy, as storm etc.It is at present domestic that to pass through the 2nd approach developer in the majority.
Can diet products really lose weight, and must satisfy two conditions: 1, respiratory quotient is between 0.65～0.75; 2, in blood and urine, the label of lipid metabolism intermediate product should be arranged, as the ketoboidies body etc.Fat-reducing is to remove or consume intravital superabundant fats at all, and commercially available diet food miscellaneous at present, removal be mostly retention at the intravital excessive moisture of machine, do not play the effect of real fat-reducing.Some methods of weight-reducing are to lose weight by the two kinds of approach of going on a diet and suffer from diarrhoea, and going on a diet makes human body can not obtain the required nutritional labeling of homergy, and diarrhoea then makes the nutritional labeling of being taken in not absorb, these two kinds of methods all cause human nutrition bad, physically-draining, giddy etc., infringement health.And this method of weight-reducing is reversible, in case stop using, will be returned to original fat state.
For this reason, we research and develop out a kind of novel healthy food or medicine, and this weight-reducing product both can be nursed one's health diet, contain 2 kinds of active component with remarkable effect of weight reducing again, i.e. chitosan and L-carnitine (the wherein adsorbable bile acid of chitosan and cholesterol and fat; And the L-carnitine can make full use of fat, fat is become energy and loses weight), thereby obesity is played a role from many aspects, really realize removing fat, consume fat and the effect of fat-reducing.Compare with traditional method of weight-reducing, this weight-reducing product has not only been avoided the infringement of reversible fat-reducing to body, also makes body replenish energy, keeps abundant, vigorous energy, this method meet three standards of the health slimming of World Health Organization (WHO) regulation: not anorexia, not weak, do not suffer from diarrhoea.
Summary of the invention
The health food or the medicine that the purpose of this invention is to provide a kind of integrated control obesity, this health food or medicine are from regulating the effect of 3 aspects such as diet, conversion fat, binding fat to obesity performance control.
Another object of the present invention is first Rhizoma amorphophalli, chitosan and L-carnitine to be united use, and the present invention regulates diet by Rhizoma amorphophalli, reduces the picked-up of excess energy; By chitosan absorption of bile acid and cholesterol and fat, reduce fat and the necessary precursor of synthctic fat, to remove fat; By L-carnitine trans-utilization fat, fat is become energy and lose weight, to consume superabundant fats.
The object of the present invention is achieved like this:
Health food provided by the invention or medicine are that following one-tenth is grouped into, and by weight percentage, comprising:
Carnitine 40～45%;
Chitosan 30～35%;
Rhizoma amorphophalli 20～25%;
Flavoring agent 5～10%;
Product of the present invention is solid-state sprills or granule, can make various dosage forms as required, as makes tablet or capsule.
L-carnitine in health food of the present invention or the medicine.Carnitine is a kind of and the relevant micromolecular compound of animal body fat acid metabolic, and it normally is present in the human body, plays to carry long-chain fatty acid and enter mitochondrion by mitochondrial membrane, carries out the effect that beta oxidation releases energy then.The physiological function of L-carnitine shows three aspects: (1) is transported to long-chain fatty acid in the position-mitochondrial membrane of its oxidation as the form of carrier with acyl outside mitochondrial membrane, plays the effect that promotes the fatty acid beta oxidation; (2) acetyl-CoA is transported to the synthetic position of extramitochondrial long-chain fatty acid in mitochondrion, makes acetyl-CoA be used for the synthetic of fatty acid and cholesterol, help the metabolism of energy; (3) acyl group excessive in the body is discharged, eliminate body, can also promote the oxidation of acetoacetic acid, work in the degraded of ketoboidies with in utilizing because of the metabolism toxicity that the acyl group accumulation causes.The high concentration carnitine can increase the oxidative metabolism speed of fat, so the L-carnitine is the important factor of control fatty acid metabolism, if fat cans be compared to fuel, carnitine then is an oxygen so, and the burning of fuel be unable to do without oxygen, and oxygen is sufficient more, and it is fast more that fuel combustion gets speed.Just because of this, carnitine can reduce the lipopexia in blood under the various situations and the tissue, and additional carnitine can reduce the fat mass of various tissues, especially when body fat increases (as the overweight people).In health food of the present invention or medicine, the effect that the L-carnitine can play and transform fat, consume fat.
Chitosan is a cationic polymer unique in the eatable cellulose in health food of the present invention or the medicine, is third generation functional food, has immunomodulating, blood sugar lowering, brings high blood pressure down, effect such as blood fat reducing, inhibition tumor, toxin expelling.Experiment confirm, chitosan can form gel with the gastric acid effect under one's belt, under the PH of enteral condition, can keep this gel not decompose, and the effect of absorption of bile acid and cholesterol is arranged, the chitosan gel rubber that has adsorbed bile acid and cholesterol is along with feces excretes, thereby reduced the cholesterol in the blood.Simultaneously chitosan has also adsorbed fat, prevents that intestinal from digesting and assimilating fat, has reduced the fat in the blood.In health food of the present invention or medicine, chitosan can play the effect of removing fat.
Rhizoma amorphophalli contains the glucomannan about 60% in health food of the present invention or the medicine, be water soluble dietary fiber, contain protein, fat, mineral element etc. in the Rhizoma amorphophalli simultaneously, many modern studies have proved that Rhizoma amorphophalli has different physiological roles such as the enterokinesia of promotion, blood pressure lowering, blood sugar lowering, cholesterol reducing, relieving constipation.SKGM has characteristics such as water absorption is strong, viscosity is big, expansion rate height, enter in the stomach after, absorb inflatable 50～100 times of gastric juice, produce satiety, and then regulate diet, play the effect of fat-reducing.
Flavoring agent among the present invention is an aspartame, also can be other sweeting agent.
Important being characterised in that of the present invention is combined the composition of different action principles dexterously, makes their synergism by different way, and then reaches the effect of fat-reducing.First L-carnitine can quicken the catabolism of fat, and this is from lipogenesis and decomposes two aspect effects that the effect after its combination is more much higher than unilaterally.It two is chitosan absorbing fats, stops fat to enter in the body, and this just loses weight from " advancing " and " going out " two aspects of fat, and its effect is more far better than unilaterally losing weight.It three is SKGM scalable diet, and this loses weight from fat " picked-up " aspect.Therefore, the organic cooperation of three is taken, and its effect is better than taking heavy dose of one-component effect for a long time.
In health food of the present invention or the medicine, because carnitine, chitosan and SKGM have different physiological roles simultaneously: blood sugar lowering, blood fat reducing, blood pressure lowering, adjusting immunity etc., just avoided, so triplicity also has certain complement function like this because of problems such as undernutrition that fat-reducing causes, physical weakness.
Compared with the prior art the present invention has following advantage and characteristics:
1, the fat-reducing mechanism of weight-reducing product of the present invention is clear and definite, and fat-reducing effect is obvious.
2, not only fat-reducing effect is obvious for this weight-reducing product, and has avoided because of the infringement of fat-reducing to body, makes body keep abundant, and vigorous energy meets three standards of health slimming.
3, the mouthfeel of weight-reducing product of the present invention is better.
4, the preparation method technology of weight-reducing product of the present invention is simple, easy to operate.
The specific embodiment
Embodiment 1
Adopt the SD rat, after setting up the fat model of rat, be divided at random: fat matched group, normal control group, 1 group of experiment and test 2 groups, animal continues to feed the high heat feedstuff, and the normal control group is fed normal diet, freely drinks water, takes food.Test 1 group of 0.5g weight-reducing product/100g body weight with irritating 10 o'clock every mornings of stomach mode, test 2 group of 1 g weight-reducing product/100g body weight, matched group is irritated distilled water (1ml/100g body weight), carries out the animal weight-reducing experiment, and experiment periods was 2 weeks.The result shows:
1., product of the present invention can make female rats obviously fat-reducing and triglyceride reducing, male rat does not have obvious effect (table 1);
2., product of the present invention can obviously reduce the excessive storage of glycogen in the obese rat hepatocyte, recovers hepatocellular normal morphology, female rats is (table 2) particularly significantly;
3., experiment periods is not found ill effect.
Table 1 group quantity weight increase fat content fat-body anharmonic ratio normal control female 6 13.7 ± 7.1 4.9 ± 1.3 0.02 ± 0.01
Female 5 23.6 ± 16.4 13.6 ± 6.7a, the 0.05 ± 0.02a of male 6 28.3 ± 16.4 3.6 ± 1.4 0.01 ± 0.001 fat contrasts
Male 7 57.0 ± 8.0a, 8.6 ± 2.7a, 0.03 ± 0.01a tests 1 group female 6 16.3 ± 7.6 11.1 ± 4.6 0.04 ± 0.02
Male 6 57.3 ± 20.2a, 7.0 ± 2.6a, 0.02 ± 0.01a tests 2 groups of female 6 7.5 ± 17.4abc 8.6 ± 5.4 0.03 ± 0.02
Male 7 0.6 ± 27.3abc, 6.4 ± 2.2a, 0.02 ± 0.01aa: compare significant difference with normal control; B: compare significant difference with the obesity contrast; C: compare significant difference for 1 group with experiment
Table 2 group quantity cholesterol triglyceride normal control female 6 2.09 ± 0.20 0.82 ± 0.20
Female 5 2.37 ± 0.43 2.28 ± 0.71a of male 6 2.09 ± 0.26 1.05 ± 0.38 fat contrasts
Male 7 2.09 ± 0.23 3.90 ± 0.72a test 1 group of female 6 2.22 ± 0.23 1.99 ± 0.65a
Male 6 2.43 ± 0.30 2.60 ± 1.15a test 2 groups of female 6 2.47 ± 0.24 1.20 ± 0.35b
Male 7 2.66 ± 0.45ab, 3.02 ± 1.24aa: compare significant difference with normal control; B: compare significant difference with the obesity contrast;
Embodiment 2
109 routine patients are the body weight body weight that is above standard, voluntary participation weight-reducing experiment person, trial edition invention weight-reducing product, the result shows:
1, weight-reducing product shows 109 routine obese patients' observation, and total effective rate and total obvious effective rate are respectively 88.07%, 47.7% (table 3);
Table 3: the total obvious effective rate of routine number clinical cure produce effects enabledisable total effective rate 109 16 36 44 13 88.07% 47.7%
2, weight-reducing product has hypertensive patient concurrently to obesity, and medication bleeding from anus pressure drop to normal total effective rate is 69.4% (table 4);
Table 4
Treatment back recovery rate (%) before the treatment
36 people, 11 people 69.4
3, weight-reducing product has the patient of hyperlipemia concurrently to obesity, and to reduce to normal total effective rate be 80% (table 5) to blood fat after the medication.
Table 5
Treatment back recovery rate (%) before the treatment
30 people, 6 people 80.0
Claims (4)
1, a kind of fat-reducing medicine or health food is characterized in that, this blood sugar lowering medicine or health food are primary raw material with chitosan, Rhizoma amorphophalli and carnitine, add flavoring agent again, adopt conventional method to make.
2, fat-reducing medicine as claimed in claim 1 or health food is characterized in that, each proportioning raw materials by weight percentage, for:
Carnitine 40～45%;
Chitosan 30～35%;
Rhizoma amorphophalli 20～25%;
Flavoring agent 5～10%.
3, fat-reducing medicine as claimed in claim 1 or 2 or health food is characterized in that, described flavoring agent is an aspartame, also can be other sweeting agents.
4, a kind ofly it is characterized in that as any described fat-reducing medicine of claim 1-3 or health food this fat-reducing medicine or health food are solid-state sprills or granule, can make various dosage forms as required, as making tablet or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN01142084A CN1406622A (en) | 2001-09-11 | 2001-09-11 | High efficiency weight reduction medicine or health-care food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN01142084A CN1406622A (en) | 2001-09-11 | 2001-09-11 | High efficiency weight reduction medicine or health-care food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1406622A true CN1406622A (en) | 2003-04-02 |
Family
ID=4676615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN01142084A Pending CN1406622A (en) | 2001-09-11 | 2001-09-11 | High efficiency weight reduction medicine or health-care food |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1406622A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331423C (en) * | 2004-04-30 | 2007-08-15 | 南阳市海达生物技术有限公司 | Food for relaxing bowel and reducing body weight and its preparation method |
| CN101524154B (en) * | 2009-04-07 | 2012-07-25 | 北京康比特体育科技股份有限公司 | Fat reducing food bar |
| CN102715392A (en) * | 2012-07-06 | 2012-10-10 | 张文彪 | Food with weight reducing function |
| CN103156171A (en) * | 2011-12-12 | 2013-06-19 | 朱兵 | Slimming tablet and preparation method thereof |
| CN103156170A (en) * | 2011-12-12 | 2013-06-19 | 朱兵 | Blood sugar-reducing tablet and preparation method thereof |
| CN105326053A (en) * | 2015-10-03 | 2016-02-17 | 王保红 | L-carnitine and chitosan oligosaccharide-containing composition and preparation method and application |
| CN106072673A (en) * | 2016-07-08 | 2016-11-09 | 宝健（北京）生物技术有限公司 | A kind of compositions that can effectively reduce body fat ratio |
| CN108142935A (en) * | 2018-01-24 | 2018-06-12 | 上海市第十人民医院 | A kind of slimming capsule that natural polymer subbase gel inner nuclear material is controllably constructed based on dynamic chemical key |
| CN108378355A (en) * | 2018-01-06 | 2018-08-10 | 福建古瑞森生物科技有限公司 | Reducing diabetes B patient's postprandial blood sugar improves the alimentation composition pre- before the meal and preparation method thereof that blood fat increases intestinal beneficial bacterium |
-
2001
- 2001-09-11 CN CN01142084A patent/CN1406622A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331423C (en) * | 2004-04-30 | 2007-08-15 | 南阳市海达生物技术有限公司 | Food for relaxing bowel and reducing body weight and its preparation method |
| CN101524154B (en) * | 2009-04-07 | 2012-07-25 | 北京康比特体育科技股份有限公司 | Fat reducing food bar |
| CN103156171A (en) * | 2011-12-12 | 2013-06-19 | 朱兵 | Slimming tablet and preparation method thereof |
| CN103156170A (en) * | 2011-12-12 | 2013-06-19 | 朱兵 | Blood sugar-reducing tablet and preparation method thereof |
| CN102715392A (en) * | 2012-07-06 | 2012-10-10 | 张文彪 | Food with weight reducing function |
| CN102715392B (en) * | 2012-07-06 | 2013-11-06 | 张文彪 | Food with weight reducing function |
| CN105326053A (en) * | 2015-10-03 | 2016-02-17 | 王保红 | L-carnitine and chitosan oligosaccharide-containing composition and preparation method and application |
| CN106072673A (en) * | 2016-07-08 | 2016-11-09 | 宝健（北京）生物技术有限公司 | A kind of compositions that can effectively reduce body fat ratio |
| CN108378355A (en) * | 2018-01-06 | 2018-08-10 | 福建古瑞森生物科技有限公司 | Reducing diabetes B patient's postprandial blood sugar improves the alimentation composition pre- before the meal and preparation method thereof that blood fat increases intestinal beneficial bacterium |
| CN108142935A (en) * | 2018-01-24 | 2018-06-12 | 上海市第十人民医院 | A kind of slimming capsule that natural polymer subbase gel inner nuclear material is controllably constructed based on dynamic chemical key |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109170459A (en) | A kind of albumen cereal fruit-vegetable powder solid beverage and preparation method | |
| CN1406622A (en) | High efficiency weight reduction medicine or health-care food | |
| CN103463407B (en) | Reason machine Jiangtang capsule | |
| CN107787191B (en) | Composition for weight loss comprising a beverage and beads | |
| CN108771081A (en) | Haematococcus pluvialis citrus fruit fibres compound solid beverage of weight-reducing and preparation method thereof | |
| CN109316565B (en) | Blood fat reducing composition and preparation method and application thereof | |
| KR100532556B1 (en) | Composition for treating obesity and constipation containing extract of pine needle, green tea and black tea as an active ingredient | |
| CN101584706A (en) | Pharmaceutical composition used for reducing blood sugar and blood fat and treating diabetes | |
| CN101491584A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN101596276A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat and treatment diabetes | |
| CN101584709A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat and treatment diabetes | |
| Vyas | Effect of fenugreek (Methi dana) on carbohydrate and protein metabolism in diabetic patients | |
| CN101574370A (en) | Drug composition for reducing blood sugar and blood fat | |
| CN1861173A (en) | Edible cellulose powder used as nutrient therapy medicine for diabetic | |
| CN1429587A (en) | Ginkgo leaf compound preparation for improving cardiovascular and cerebrovascular blood supply | |
| CN101579463A (en) | Medicine composition for reducing blood sugar and blood fat, and curing diabetes | |
| CN101474302A (en) | Pharmaceutical composition for reducing blood sugar | |
| CN101596281A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat | |
| CN101045135A (en) | Medicine use for improving memory and treating senile dementia due to encephalatrophy | |
| CN101632790A (en) | Drug combination for reducing blood sugar level | |
| CN101574462A (en) | Drug composition for reducing blood sugar and blood fat and curing diabetes | |
| CN101596284A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat | |
| CN101584710A (en) | Pharmaceutical composition used for reducing blood sugar and blood fat and treating diabetes | |
| CN101628027A (en) | Drug combination for reducing blood sugar and lipid levels and treating diabetes | |
| CN101632770A (en) | Drug combination for reducing blood sugar and lipid levels and treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |